BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
65.29
-0.32 (-0.49%)
At close: Aug 27, 2026, 4:00 PM EDT
64.00
-1.29 (-1.98%)
After-hours: Aug 27, 2026, 5:28 PM EDT
BioMarin Pharmaceutical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,407 | 3,221 | 2,854 | 2,419 | 2,096 | 1,846 | |
Revenue Growth | 11.20% | 12.87% | 17.97% | 15.42% | 13.53% | -0.76% |
Cost of Revenue | 1,670 | 1,520 | 1,327 | 1,279 | 1,153 | 1,099 |
Gross Profit | 1,736 | 1,701 | 1,526 | 1,140 | 943.41 | 746.97 |
Selling, General & Admin | 1,149 | 1,031 | 1,009 | 892.41 | 823.24 | 759.38 |
Amortization of Goodwill & Intangibles | 87.67 | 19.39 | 43.26 | 62.21 | 65.49 | 61.91 |
Operating Expenses | 1,237 | 1,050 | 1,052 | 954.62 | 888.73 | 821.28 |
Operating Income | 499.75 | 650.73 | 474.21 | 185.77 | 54.68 | -74.32 |
Interest Expense | -83.61 | -10.9 | -12.67 | -17.34 | -15.97 | -15.34 |
Interest & Investment Income | 70.1 | 74.9 | 74.88 | 58.34 | 18.03 | 10.48 |
Currency Exchange Gain (Loss) | - | - | - | - | -11.4 | - |
Other Non Operating Income (Expenses) | 13.36 | 9 | -4.67 | -38.22 | -2.06 | 11.85 |
EBT Excluding Unusual Items | 499.6 | 723.73 | 531.76 | 188.56 | 43.28 | -67.32 |
Merger & Restructuring Charges | -350.49 | -241.25 | - | - | - | - |
Gain (Loss) on Sale of Assets | - | - | 10 | - | 108 | - |
Other Unusual Items | - | - | - | - | -1.7 | -8.03 |
Pretax Income | 149.11 | 482.48 | 541.76 | 188.56 | 149.58 | -75.35 |
Income Tax Expense | 76.14 | 133.58 | 114.9 | 20.92 | 8.02 | -11.27 |
Net Income | 72.97 | 348.9 | 426.86 | 167.65 | 141.56 | -64.08 |
Net Income to Common | 72.97 | 348.9 | 426.86 | 167.65 | 141.56 | -64.08 |
Net Income Growth | -88.90% | -18.26% | 154.62% | 18.43% | - | - |
Shares Outstanding (Basic) | 193 | 192 | 190 | 188 | 185 | 183 |
Shares Outstanding (Diluted) | 196 | 197 | 197 | 192 | 189 | 183 |
Shares Change | 0.61% | 0.35% | 2.67% | 1.39% | 3.34% | -4.61% |
EPS (Basic) | 0.38 | 1.82 | 2.25 | 0.89 | 0.76 | -0.35 |
EPS (Diluted) | 0.38 | 1.80 | 2.21 | 0.87 | 0.75 | -0.35 |
EPS Growth | -88.85% | -18.24% | 153.71% | 16.00% | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 738.18 | 724.96 | 487.42 | 62.57 | 54.94 | 208.96 |
Free Cash Flow Per Share | 3.76 | 3.67 | 2.48 | 0.33 | 0.29 | 1.14 |
Gross Margin | 50.97% | 52.81% | 53.49% | 47.14% | 45.01% | 40.46% |
Operating Margin | 14.67% | 20.20% | 16.62% | 7.68% | 2.61% | -4.03% |
Profit Margin | 2.14% | 10.83% | 14.96% | 6.93% | 6.75% | -3.47% |
Free Cash Flow Margin | 21.67% | 22.50% | 17.08% | 2.59% | 2.62% | 11.32% |
EBITDA | 645.32 | 722.89 | 570.64 | 290.16 | 156.65 | 33.72 |
EBITDA Margin | 18.94% | 22.44% | 19.99% | 11.99% | 7.47% | 1.83% |
D&A For EBITDA | 145.57 | 72.16 | 96.43 | 104.39 | 101.97 | 108.04 |
EBIT | 499.75 | 650.73 | 474.21 | 185.77 | 54.68 | -74.32 |
EBIT Margin | 14.67% | 20.20% | 16.62% | 7.68% | 2.61% | -4.03% |
Effective Tax Rate | 51.06% | 27.69% | 21.21% | 11.09% | 5.36% | - |
Revenue as Reported | 3,407 | 3,221 | 2,854 | 2,419 | 2,096 | 1,846 |
Advertising Expenses | - | 50.5 | 34.5 | 27.8 | 25.2 | 30.2 |